Board-Certified Oncologist & Hematologist in Puyallup and Bonney Lake, WA
Dr. Kanaan is a board-certified Medical Oncologist and Hematologist with specialized expertise in genitourinary (GU) malignancies—including prostate, bladder, kidney, and testicular cancers—along with hematologic disorders and cutaneous malignancies.
He completed his Hematology and Oncology fellowships at Michigan State University and the University of Arizona, following his Internal Medicine residency at Michigan State University / McLaren Regional Medical Center.
Dr. Kanaan currently serves as Medical Director at Northwest Medical Specialties (NWMS) and Director of Operations and Provider Relations. He is the Chair of both the GU Committee and the Quality Committee at OnCare Alliance, and he leads the Theranostics Program at NWMS.
He has authored and presented numerous research publications and abstracts at national meetings, including ASCO and ASH.
Outside of medicine, Dr. Kanaan enjoys hiking, mountain biking, soccer, swimming, and cycling.
Residency: McLaren Medical Center at Michigan State University
Fellowships: Michigan State University, University of Arizona
Board Certifications: Medical Oncology, Hematology, Internal Medicine
Peer-Reviewed Publications:
- 1. Dumbrava EE, Stinchcombe TE, Gounder M, et al., Kanaan M, et al. Milademetan in advanced solid tumors with MDM2 amplification and wild-type TP53: Preclinical and phase II clinical trial results. Clin Cancer Res. 15 Oct 2025; 31(20): 4255-4264. DOI: 10.1158/1078-0432.CCR-25-0762.
2. Mallahan S, Gajra A, Blau S, et al., Kanaan M, et al. Optimizing clinical trial subject selection: Insights from Exigent Research Network and the Tempus AI TIME program collaboration. AI Prec Oncol. 18 Dec 2024; 1(6). DOI: 10.1089/aipo.2024.0030.
3. Dumbrava EE, Chen CT, Cote GM, et al., Kanaan M, et al. Abstract B034: A phase 2 basket study of the oral MDM2 inhibitor milademetan for MDM2-amplified advanced solid tumors (MANTRA-2). Mol Cancer Ther. 1 Dec 2023; 22(12_Supplement): B034. DOI: 10.1158/1535-7163.TARG-23-B034.
4. Sirop S, Kanaan M, Korant A, Wiese D, Eilender D, Nagpal S, Arora M, Singh T, Saha S. Detection and prognostic impact of micrometastasis in colorectal cancer. J Surg Oncol. 2011 May 1;103(6):534-7. doi: 10.1002/jso.21793.
5. Acharya UH, Halpern AB, Wu QV, Voutsinas JM, Walter RB, Yun S, Kanaan M, Estey EHII. Impact of region of diagnosis, ethnicity, age, and gender on survival in acute myeloid leukemia (AML). J Drug Assess. 2018 Jul 10;7(1):51-53. doi: 0.1080/21556660.2018.1492925. eCollection 2018.
6. Rogowitz E, Babiker HM, Kanaan M, Millius RA, Ringenberg QS, Bishop M. Neuroblastoma of the elderly, an oncologist’s nightmare: case presentation, literature review and SEER database analysis. Exp Hematol Oncol. 2014 Jul 17;3:20. doi: 10.1186/2162-3619-3-20. ECollection.
7. Saha S, Johnston G, Korant A, Shaik M, Kanaan M, Johnston R, Ganatra B, Kaushal S, Desai D, Mannam S. Aberrant drainage of sentinel lymph nodes in colon cancer and its impact on staging and extent of operation. Am J Surg. 2013 Mar;205(3):302-5; discussion 305-6. doi: 10.1016/j.amjsurg.2012.10.029. PMID: 234149.
8. Saha S, Sirop S, Korant A, Kanaan M, Shekher R, Strahle D, Hicks M, Hicks R, Lawrence L, Wiese D. Nodal positivity in breast cancer correlated with the number of lesions detected by magnetic resonance imaging versus mammogram. Am J Surg. 2011 Mar;201(3):390-4; discussion 394-5. doi: 10.1016/j.amjsurg.2010.11.006. PMID: 2136738.